Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

324
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
324
Lineage Commitment01:21

Lineage Commitment

3.0K
Commitment is the  process whereby stem cells:
3.0K
Human Genetics01:28

Human Genetics

559
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
559
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mutations01:39

Mutations

81.9K
Overview
81.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

British journal of haematology·2026
Same author

Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasms.

Blood advances·2026
Same author

p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases.

American journal of hematology·2026
Same author

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same author

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Journal of hematology & oncology·2026

相关实验视频

Updated: Jun 25, 2025

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.1K

血液恶性瘤中的生殖线倾向:测试,管理和影响

Lucy A Godley1, Courtney D DiNardo2, Kelly Bolton3

  • 1Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Northwestern University, Chicago, IL.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
|May 20, 2024
PubMed
概括
此摘要是机器生成的。

生殖线DNA变异增加了髓状骨髓瘤恶性瘤的风险. 基因检测,现在更容易获得和保险覆盖,使得个性化癌症监测和潜在的预防策略受影响的个体.

更多相关视频

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.6K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

相关实验视频

Last Updated: Jun 25, 2025

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.1K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.6K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

科学领域:

  • 遗传学 遗传学 是一个
  • 在瘤学瘤学.
  • 分子生物学分子生物学

背景情况:

  • 胚胎DNA变异越来越多地被认为是髓状细胞恶性瘤风险的重要贡献者.
  • 尽管存在障碍,但转诊和生殖癌症倾向性检测的可用性正在改善.
  • 遗传性骨髓瘤恶性瘤风险应考虑所有患者,无论诊断时的年龄,由于共同的倾向性等位基因和扩大疾病识别.

研究的目的:

  • 为了强调生殖线癌症倾向测试对髓状瘤恶性病的日益重要的重要性.
  • 讨论生殖线检测在临床实践中的促进者和影响.
  • 概述未来管理骨髓瘤恶性瘤遗传风险的方向.

主要方法:

  • 从培养的皮肤纤维细胞或头发球泡中获得DNA,用于生殖线检测.
  • 级联测试是有效地使用口腔拭子,唾液或血液样本进行的.
  • 这项研究回顾了关于生殖线骨髓瘤恶性倾向的当前文献和临床指导方针.

主要成果:

  • 增加对生殖系变异的识别,改善了测试转诊和可用性.
  • 对于生殖线检测的保险覆盖范围正在扩大,因为它被纳入了指导方针.
  • 细菌线检测允许进行个性化癌症监测,包括对非血液构造性和其他器官病理的查.

结论:

  • 对髓性恶性瘤倾向的生殖线检测正在变得越来越容易获得和认可.
  • 在诊断后可以制定个性化监测和潜在的预防策略.
  • 未来的研究可能会带来更广泛的建议,在骨髓性倾向条件下进行生殖线检测.